CTNM Contineum Therapeutics16.59-0.98 (-5.6%)
After Hours Decliner
CTNM Contineum Therapeutics12.22-0.21-1.7%
After Hours:11.50-0.72 (-5.9%)
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Business WireThu, 20-Nov 4:05 PM
